Testing a new imaging agent for prostate cancer surgery
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug that helps surgeons see prostate cancer during surgery. It is for men with prostate cancer who are already scheduled for robotic prostatectomy and lymph node removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have been diagnosed with prostate cancer that is aggressive or may have spread outside the prostate.
- You are scheduled to have robotic prostatectomy and lymph node dissection.
- You have had a PSMA-PET scan within the last 12 months or are scheduled to have one.
- You agree to use birth control or abstain from sex during the study and for 6 weeks after the drug dose.
- You do not have severe kidney or liver problems, and no allergy to the study drug or similar dyes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a PSMA-PET scan before prostatectomy can guide surgery in a way that helps preserve sexual function. It may be most helpful if you have certain kinds of prostate cancer and want to keep erections after surgery.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This study tests a new imaging agent (68Ga-NYM032) used with PET/CT scans to help doctors better detect prostate cancer before surgery. If you have biopsy-confirmed prostate cancer and are planning to have your prostate removed, this trial may help evaluate whether this new imaging method improves cancer detection.
This study tests a new imaging method (PET scan) that uses a special tracer to find prostate cancer cells, whether it's the first diagnosis or a recurrence after treatment. The goal is to see how well this imaging works for locating cancer in the body.
This research study tests a new imaging scan (called 68Ga-OncoACP3-PET/CT) to help find prostate cancer and see where it may have spread. The scan uses a radioactive tracer to help doctors visualize cancer cells and decide on the best treatment options.
This trial tests a new type of PET scan to see how well it finds leftover cancer after you've had focal therapy (treatment to just part of the prostate) for intermediate-risk prostate cancer in the last 9 months.
Hear when a new Prostate Cancer Surgery trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.